European Union - English - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - maribavir - cytomegalovirus infections - antivirals for systemic use - livtencity is indicated for the treatment of cytomegalovirus (cmv) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (hsct) or solid organ transplant (sot).consideration should be given to official guidance on the appropriate use of antiviral agents.

Egypt - English - EDA (Egyptian Drug Authority)

city pharma -egypt - sulphadimidine sodium 100 gm (equivalent to 92.67 gm sulphadimidine base) /100gm - water soluble powder

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - maribavir, quantity: 200 mg - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; sodium starch glycollate; titanium dioxide; purified talc; brilliant blue fcf aluminium lake; polyvinyl alcohol; macrogol 3350 - treatment of adults with post-transplant cytomegalovirus (cmv) infection and disease resistant, refractory or intolerant to one or more prior therapies (see 4.3 contraindications and, 4.4 special warnings and precautions for use).

Israel - English - Ministry of Health

takeda israel ltd - maribavir - film coated tablets - maribavir 200 mg - maribavir - livtencity is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (cmv) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Egypt - English - EDA (Egyptian Drug Authority)

city pharma a.r.e - flunixin meglumine 8.3 gm equivalent to 5 gm flunixin. - injectable solution

Egypt - English - EDA (Egyptian Drug Authority)

city pharma - oxytetracycline hcl 62.5 mg (equivalent to oxytetracycline base 50 mg)/1ml - solution for injection

Canada - English - Health Canada

takeda canada inc - maribavir - tablet - 200mg - maribavir 200mg

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - maribavir (unii: ptb4x93he1) (maribavir - unii:ptb4x93he1) - livtencity is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (cmv) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see use in specific populations (8.4) and clinical studies (14)] . none. risk summary no adequate human data are available to establish whether livtencity poses a risk to pregnancy outcomes. in animal reproduction studies, embryo-fetal survival was decreased in rats, but not in rabbits, at maribavir exposures less than those observed in humans at the recommended human dose (rhd) (see data) . the background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data in a combined ferti

Australia - English - Department of Health (Therapeutic Goods Administration)

regulatory services australia - homosalate, quantity: 80 mg/g; butyl methoxydibenzoylmethane, quantity: 30 mg/g; octyl salicylate, quantity: 40 mg/g; octocrylene, quantity: 20 mg/g - lotion - excipient ingredients: purified water; octanohydroxamic acid; caprylyl glycol; glycerol; panthenyl triacetate; ethyl linoleate; oleyl alcohol; dl-alpha-tocopherol; dexpanthenol; trolamine; xanthan gum; disodium edetate; peg-40 stearate; silicon dioxide; cetostearyl alcohol; isostearyl neopentanoate; ceteareth-20; cetyl dimeticone; cyclomethicone; ammonium acryloyldimethyltaurate/vp copolymer; polypropylene; triacontanyl pvp; lactic acid; sodium chloride; sorbitol; pentylene glycol; sodium lactate; serine; urea; allantoin

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - calcium polystyrene sulfonate 99.93% (binding capacity 1.7meq/g);  ;   - powder for oral solution - 1.7 meq/g - active: calcium polystyrene sulfonate 99.93% (binding capacity 1.7meq/g)     excipient: saccharin vanillin